Overview

  • Product nameICI 182,780
  • Description
    Estrogen receptor antagonist
  • Alternative names
    • Fulvestrant
  • Biological descriptionEstrogen receptor antagonist with no partial agonist activity. Anticancer agent (IC50 = 0.29 nM for inhibition of breast cancer cell growth). Causes downregulation and loss of estrogen receptors.
  • Purity> 99%

Properties

    Applications

    Our Abpromise guarantee covers the use of ab120131 in the following tested applications.

    The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

    Application Abreviews Notes
    Functional Studies Use at an assay dependent concentration.

    ICI 182,780 images

    • ab47489 staining BCL2 in MCF7 cells treated with ICI 182,780 (ab120131), by ICC/IF. Decrease in BCL2 expression correlates with increased concentration of ICI 182,780 as described in literature.
      The cells were incubated at 37°C for 3h in media containing different concentrations of ab120131 (ICI 182,780) in DMSO, fixed with 4% formaldehyde for 10 minutes at room temperature and blocked with PBS containing 10% goat serum, 0.3 M glycine, 1% BSA and 0.1% tween for 2h at room temperature. Staining of the treated cells with ab47489 (5 µg/ml) was performed overnight at 4°C in PBS containing 1% BSA and 0.1% tween. A DyLight 488 goat anti-rabbit polyclonal antibody (ab96899) at 1/250 dilution was used as the secondary antibody. Nuclei were counterstained with DAPI and are shown in blue.

    References for ICI 182,780 (ab120131)

    This product has been referenced in:
    • Zhao L  et al. Estrogenic agonist activity of ICI 182,780 (Faslodex) in hippocampal neurons: implications for basic science understanding of estrogen signaling and development of estrogen modulators with a dual therapeutic profile. J Pharmacol Exp Ther 319:1124-32 (2006). Read more (PubMed: 16951259) »
    • Lim KB  et al. Induction of apoptosis in mammary gland by a pure anti-estrogen ICI 182780. Breast Cancer Res Treat 68:127-38 (2001). Read more (PubMed: 11688516) »
    • Wakeling AE  et al. A potent specific pure antiestrogen with clinical potential. Cancer Res 51:3867-73 (1991). Read more (PubMed: 1855205) »

    See all 2 Publications for this product

    Product Wall

    There are currently no Abreviews or Questions for ab120131.
    Please use the links above to contact us or submit feedback about this product.

    Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE, NOT FOR USE IN HUMANS"